X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

apceth Biopharma Appoints a New Supervisory Board

Yuvraj_pawp by Yuvraj_pawp
9th November 2017
in Americas, News

apceth Biopharma GmbH, a leading company developing the next generation of cell-based therapies, announced today the appointment of a new Supervisory Board.

The Supervisory Board will be responsible for advising and supporting the company on its corporate and business strategies. The Board is composed of highly experienced members with successful track records in the pharma and biotech industry. Manfred Ruediger, Chairman, is a seasoned senior executive with over 20 years’ experience in leading biotech companies both at the management and board levels. He also has an extensive knowledge in advancing cell-based therapies towards late-stage clinical development and pre-commercialization stages. Hans-Jochem Kolb is a world renowned expert in the field of hematological oncology and a pioneer in cellular immunotherapy and bone marrow/stem cell transplantation. He performed the first successful bone marrow transplantation in Germany and is active today as a consultant for various universities and biotech companies.

Matthias Kromayer is a member of the Executive Board of MIG Verwaltungs AG which is responsible for the MIG Funds’ life sciences holdings. He has a comprehensive background in strategic consulting and has advised more than 30 companies on their corporate strategy.
Klaus Schollmeier has more than 30 years’ experience as a senior executive and advisor in the biotech industry as well as in investment banking. He serves as board member of several European biotech companies. “I am very pleased to welcome our new Supervisory Board, whose outstanding expertise and leadership will help us to successfully achieve our goals of bringing the next generation of cell-based gene therapies to patients with difficult to treat diseases,” said Christine Guenther, apceth Biopharma’s CEO.

“These are exciting times for apceth. apceth has been very successfully growing and expanding its profitable contract development and manufacturing business for cell-based therapeutics. At the same time, they are also advancing the development of their product candidate apceth-201 in graftversus-host disease and apceth-301 in glioblastoma. Both diseases present huge unmet medical needs where innovative approaches are needed to change patients’ fates and they offer highly attractive commercial opportunities,” commented Manfred Ruediger, Chairman of the Supervisory Board, and added: “We look forward to working closely with Christine and her team to continue apceth’s growth and success.”

About apceth Biopharma GmbH
apceth Biopharma is a leading company in cell-based gene therapeutics with an innovative portfolio of drug candidates for the treatment of chronic inflammation, autoimmunity (immunomodulation) and solid cancer (immuno-oncology). Through introduction of different therapeutic transgenes into Mesenchymal Stem Cells (MSCs), apceth is developing two potent next generation MSC-based gene therapy products. apceth-201 expresses the immunomodulatory protein Alpha-1 Antitrypsin for the treatment of graft-versus-host disease. The company’s second program, apceth-301, expresses a potent immunostimulatory “cocktail” of cytokines which locally activates the immune system to eradicate tumor cells. apceth-301 is currently being developed for glioblastoma.

apceth is also an experienced and certified Contract Development & Manufacturing Organization for Advanced Therapy Medicinal Products (ATMPs) with a high international reputation for professionalism, quality and reliability. The company has state-of-the-art manufacturing facilities (ISO 5, ISO 7, ISO 8, BSL2 cleanrooms), is certified for GMP production, and has an extensive quality management system, allowing apceth to ensure full regulatory compliance as well as the utmost GMP and quality standards according to regulatory requirements for ATMPs. apceth has successfully obtained multiple manufacturing licenses for different types of native and genetically engineered cells and cell-based products. apceth was the first company worldwide to obtain approval for the clinical testing of genetically engineered MSCs in patients. Irrespectively of the type of cells and cell products (native or genetically engineered HSCs, MSCs, and immune cells), or the cell source, apceth provides fully customized solutions in the development and production of every customer product and process. Located centrally in the heart of Europe, apceth can perform efficient and fast supply of the client’s products across the continent.

Contact
apceth Biopharma GmbH
Dr Christine Guenther, CEO
Max-Lebsche-Platz 30
81377 Munich
Germany
Phone: +49 (0)89 7009608 0
Email: contact@apceth.com
www.apceth.com

Previous Post

GNS Healthcare Names Dr. David Sontag to its Strategic Advisory Board

Next Post

Recipharm to end operations in two facilities in Sweden

Related Posts

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

GSK Commits £1 Billion To Combat Infections In Poor Nations

27th June 2022
Next Post

Recipharm to end operations in two facilities in Sweden

Latest News

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In